Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 15

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

HIV infection

Recruiting

A Study of Venetoclax in People with HIV-1 Infection Starting Antiretroviral Treatment to Reduce the HIV Reservoir

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Region Midtjylland

Cardiac amyloidosis

Recruiting

A Study of Acoramidis in Adult Patients with Transthyretin Amyloidosis with Cardiomyopathy Who Previously Received Tafamidis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Bayer Consumer Care AG

Dermatitis atopic

Recruiting

Testing two moisturizing creams with urea, propylene glycol, and propylene glycol alone for preventing flare-ups in patients with atopic dermatitis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Propylene Glycol
  • Sponsor:Galenica AB

Systemic scleroderma+3

Recruiting

A Study of Idecabtagene Vicleucel CAR-T Cell Therapy for Patients with Autoimmune Diseases That Did Not Respond to B Cell Removal Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Idecabtagene Vicleucel
  • Sponsor:Universitaetsklinikum Erlangen AöR

Transplant rejection+1

Recruiting

A Study of Belimumab to Help Identify Safe Kidney Transplant Matches in Patients with High Antibody Levels Against Donor Tissue Types

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Atopic keratoconjunctivitis

Recruiting

A study testing DFL24498 eye drop solution to improve eye itching in adults with atopic keratoconjunctivitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-Ethyl-34-[(E,2R)-Hex-4-En-2-Yl]-4,7,10,12,15,19,25,28-Octamethyl-33-(Methylamino)-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-Di(Propan-2-Yl)-1-Oxa-4,7,10,13,16,19,22,25,28,31-Decazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-Undecone Hydrochloride
  • Sponsor:Dompe' Farmaceutici S.p.A.

Dermatitis atopic

Recruiting

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ro7790121
  • Sponsor:F. Hoffmann-La Roche AG

Cutaneous lupus erythematosus

Recruiting

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute graft versus host disease in skin

Recruiting

A study testing venetoclax for treating acute graft-versus-host disease in patients who received a stem cell transplant from a donor

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Medical University Of Vienna

Immune thrombocytopenia

Recruiting

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Asthma

Recruiting

Testing WIN378 Safety and Effects in Adults with Moderate or Severe Asthma

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST TSLP
  • Sponsor:Windward Bio AG

Hereditary angioedema

Recruiting

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.